sorafenib has been researched along with Blast Phase in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Comerford, CM; Langabeer, SE; Murphy, PT; Quinn, J | 1 |
| Beullens, E; Cools, J; Lierman, E; Marynen, P; Michaux, L; Pierre, P; Vandenberghe, P | 1 |
| Fesler, MJ; Petruska, PJ; Richart, JM | 1 |
| Fesler, MJ | 1 |
4 other study(ies) available for sorafenib and Blast Phase
| Article | Year |
|---|---|
Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; DNA Mutational Analysis; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Topics: Aged; Animals; Benzenesulfonates; Blast Crisis; Blotting, Western; Cells, Cultured; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Male; Mice; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Phosphorylation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Sorafenib | 2009 |
A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
Topics: Antineoplastic Agents; Benzenesulfonates; Blast Crisis; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2010 |
Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Blast Crisis; Bone Marrow Diseases; fms-Like Tyrosine Kinase 3; Humans; Inverted Repeat Sequences; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tandem Repeat Sequences | 2011 |